| Name | Title | Contact Details |
|---|
NAC Kazatomprom JSC is the national operator of the Republic of Kazakhstan for the import and export of uranium, rare metals, nuclear fuel for nuclear power plants. Since 2009, Kazakhstan has been the world leader in natural uranium mining, and Kazatomprom has priority rights to the countrys extensive reserves. National atomic company assets include the entire complex of Kazakh enterprises involved in the front-end of the nuclear fuel cycle - from geological exploration, uranium mining, and production of nuclear fuel cycle, through to scientific research and development of patented technologies.
Compliance Envirosystems is a Baton Rouge, LA-based company in the Business Services sector.
Anthem Recruiting is a Reno, NV-based company in the Business Services sector.
GoldState Music is a private investment firm with a primary focus on the music sector. Our funds invest in music rights and enterprises in need of growth or expansion capital. The firm was founded in 2022 by industry veteran Charles Goldstuck and currently has an office in West Palm Beach, FL.
CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria. CARB-X is led by Boston University and its funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services; the Wellcome Trust, a global charity based in the UK; Germanys Federal Ministry of Education and Research (BMBF); the UK Department of Health and Social Cares Global Antimicrobial Resistance Innovation Fund (UK GAMRIF); the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH) within the HHS. CARB-X is investing more than $500 million from 2016-2021 to support innovative antibiotics and other therapeutics, vaccines and rapid diagnostics. CARB-X supports the worlds largest and most innovative pipeline of preclinical products against drug-resistant infections. CARB-X focuses exclusively on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X is headquartered at Boston University School of Law.